End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13,942 ARS | +4.20% |
|
+10.93% | +49.37% |
06-25 | Out with AI, in with defensive stocks | ![]() |
06-21 | US FDA approves Roche's drug for a chronic blood disorder | RE |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an expected P/E ratio at 40.26 and 25.87 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+49.37% | 171B | - | ||
+55.19% | 801B | C+ | ||
+47.26% | 631B | B | ||
-6.09% | 359B | C+ | ||
+21.92% | 337B | B- | ||
+18.40% | 245B | B+ | ||
+3.64% | 231B | A+ | ||
+12.98% | 219B | B- | ||
-2.78% | 161B | C+ | ||
+1.24% | 121B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AMGN Stock
- AMGN Stock
- Ratings Amgen Inc.